{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:05:41Z","timestamp":1782486341271,"version":"3.54.5"},"reference-count":42,"publisher":"Portland Press Ltd.","issue":"13","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,9]]},"abstract":"<jats:p>There have been few new treatments introduced for hypertension in the last thirty years. The endothelin (ET) system was discovered in 1988, and in the following years, it was demonstrated that it participated in the elevation of blood pressure and vascular remodeling in experimental models of hypertension, particularly those with more severe forms of hypertension. Several selective and dual antagonists of ETA receptors (ETARs) and ETB receptors (ETBRs) were developed, but none reached marketing for human hypertension. Following a successful trial in resistant hypertension, a novel antihypertensive agent has been approved in Europe and in the U.S.A.: the dual ETAR\/ETBR antagonist aprocitentan, which was recently approved for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. Thus, the time has finally arrived for ET antagonists in hypertension.<\/jats:p>","DOI":"10.1042\/cs20255853","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T12:01:50Z","timestamp":1752148910000},"page":"769-776","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Endothelin antagonists for hypertension: has their time finally arrived?"],"prefix":"10.1042","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4502-2823","authenticated-orcid":false,"given":"Ernesto L.","family":"Schiffrin","sequence":"first","affiliation":[{"name":"1Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research and Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, MGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"2025071008014924800_CS-2025-5853C1","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1161\/HYPERTENSIONAHA.119.14504","article-title":"Randomized dose-response study of the new dual endothelin receptor antagonist aprocitentan in hypertension","volume":"75","author":"Verweij","year":"2020","journal-title":"Hypertension"},{"key":"2025071008014924800_CS-2025-5853C2","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"key":"2025071008014924800_CS-2025-5853C3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/HYPERTENSIONAHA.124.24142","article-title":"Aprocitentan for blood pressure reduction in black patients","volume":"82","author":"Flack","year":"2025","journal-title":"Hypertension"},{"key":"2025071008014924800_CS-2025-5853C4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"2025071008014924800_CS-2025-5853C5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/HYPERTENSIONAHA.123.21716","article-title":"Endothelin system in hypertension and chronic kidney disease","volume":"81","author":"Schiffrin","year":"2024","journal-title":"Hypertension"},{"key":"2025071008014924800_CS-2025-5853C6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.vph.2005.03.004","article-title":"Vascular endothelin in hypertension","volume":"43","author":"Schiffrin","year":"2005","journal-title":"Vascul. Pharmacol."},{"key":"2025071008014924800_CS-2025-5853C7","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14202-5","article-title":"T cells upon activation promote endothelin 1 production in monocytes via IFN-\u03b3 and TNF-\u03b1","volume":"7","author":"Shinagawa","year":"2017","journal-title":"Sci. Rep."},{"key":"2025071008014924800_CS-2025-5853C8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000487346","article-title":"Does Endothelin-1 Raise or lower blood pressure in humans?","volume":"139","author":"Schiffrin","year":"2018","journal-title":"Nephron"},{"key":"2025071008014924800_CS-2025-5853C9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1161\/HYPERTENSIONAHA.117.09925","article-title":"THree-month endothelial human endothelin-1 overexpression causes blood pressure elevation and vascular and kidney injury","volume":"71","author":"Coelho","year":"2018","journal-title":"Hypertension"},{"key":"2025071008014924800_CS-2025-5853C10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00060.2009","article-title":"Regulation of blood pressure and salt homeostasis by endothelin","volume":"91","author":"Kohan","year":"2011","journal-title":"Physiol. Rev."},{"key":"2025071008014924800_CS-2025-5853C11","author":"Ferreira","year":"2022","edition":"4th"},{"key":"2025071008014924800_CS-2025-5853C12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/07853890.2017.1282623","article-title":"Plasma endothelin-1 levels in patients with resistant hypertension: effects of renal sympathetic denervation","volume":"49","author":"Petramala","year":"2017","journal-title":"Ann. Med."},{"key":"2025071008014924800_CS-2025-5853C13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/01.HYP.21.3.294","article-title":"Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats","volume":"21","author":"Larivi\u00e8re","year":"1993","journal-title":"Hypertension"},{"key":"2025071008014924800_CS-2025-5853C14","doi-asserted-by":"crossref","first-page":"S300","DOI":"10.1097\/00005344-200036051-00088","article-title":"Endothelin-A-receptor blockade improves renal function and doubles the lifespan of stroke-prone spontaneously hypertensive rats","volume":"36","author":"Touyz","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2025071008014924800_CS-2025-5853C15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/01.HYP.24.2.183","article-title":"Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy","volume":"24","author":"Li","year":"1994","journal-title":"Hypertension"},{"key":"2025071008014924800_CS-2025-5853C16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000159151","article-title":"Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure","volume":"33","author":"Schiffrin","year":"1996","journal-title":"J. Vasc. Res."},{"key":"2025071008014924800_CS-2025-5853C17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/hy0202.103481","article-title":"Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors","volume":"39","author":"Ammarguellat","year":"2002","journal-title":"Hypertension"},{"key":"2025071008014924800_CS-2025-5853C18","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1161\/01.CIR.0000144462.08345.B9","article-title":"Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction","volume":"110","author":"Amiri","year":"2004","journal-title":"Circulation"},{"key":"2025071008014924800_CS-2025-5853C19","first-page":"1102","article-title":"Vascular inflammation in absence of blood pressure elevation in transgenic murine model overexpressing endothelin-1 in endothelial cells","volume":"26","author":"Amiri","year":"2008","journal-title":"J Hypertens (Los Angel)"},{"key":"2025071008014924800_CS-2025-5853C20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1152\/physiolgenomics.00218.2009","article-title":"Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium","volume":"43","author":"Simeone","year":"2011","journal-title":"Physiol. Genomics"},{"key":"2025071008014924800_CS-2025-5853C21","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1161\/ATVBAHA.113.302028","article-title":"Endothelin-1 overexpression exacerbates atherosclerosis and induces aortic aneurysms in apolipoprotein E knockout mice","volume":"33","author":"Li","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2025071008014924800_CS-2025-5853C22","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/cvr\/cvaa168","article-title":"Endothelium-restricted endothelin-1 overexpression in type 1 diabetes worsens atherosclerosis and immune cell infiltration via NOX1","volume":"117","author":"Ouerd","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"2025071008014924800_CS-2025-5853C23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/HYPERTENSIONAHA.115.05168","article-title":"Inducible human endothelin-1 overexpression in endothelium raises blood pressure via endothelin type A receptors","volume":"66","author":"Rautureau","year":"2015","journal-title":"Hypertension"},{"key":"2025071008014924800_CS-2025-5853C24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/01.HYP.30.1.29","article-title":"Role for endothelin-1 in angiotensin II-mediated hypertension","volume":"30","author":"Rajagopalan","year":"1997","journal-title":"Hypertension"},{"key":"2025071008014924800_CS-2025-5853C25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/01.HYP.0000078357.92682.EC","article-title":"Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling","volume":"42","author":"Pu","year":"2003","journal-title":"Hypertension"},{"key":"2025071008014924800_CS-2025-5853C26","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/ajh\/hpac079","article-title":"Primary Aldosteronism","volume":"35","author":"Vaidya","year":"2022","journal-title":"Amer J Hypertens"},{"key":"2025071008014924800_CS-2025-5853C27","article-title":"Diagnosis and management of resistant hypertension","volume":"385","author":"Schiffrin","year":"2024","journal-title":"BMJ"},{"key":"2025071008014924800_CS-2025-5853C28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/ajh\/4.4.303","article-title":"Plasma endothelin in human essential hypertension","volume":"4","author":"Schiffrin","year":"1991","journal-title":"Am. J. Hypertens."},{"key":"2025071008014924800_CS-2025-5853C29","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1006\/bbrc.1994.1395","article-title":"Clearance of circulating endothelin-1 by ETB receptors in rats","volume":"199","author":"Fukuroda","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2025071008014924800_CS-2025-5853C30","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/01.HYP.28.4.652","article-title":"Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension","volume":"28","author":"Ergul","year":"1996","journal-title":"Hypertension"},{"key":"2025071008014924800_CS-2025-5853C31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/01.CIR.103.2.263","article-title":"Regulation of plasma endothelin by salt in salt-sensitive hypertension","volume":"103","author":"Elijovich","year":"2001","journal-title":"Circulation"},{"key":"2025071008014924800_CS-2025-5853C32","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/01.HYP.33.2.753","article-title":"Role of endothelin in the increased vascular tone of patients with essential hypertension","volume":"33","author":"Cardillo","year":"1999","journal-title":"Hypertension"},{"key":"2025071008014924800_CS-2025-5853C33","first-page":"57","article-title":"Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension","volume":"15","author":"Schiffrin","year":"1997","journal-title":"J Hypertens (Los Angel)"},{"key":"2025071008014924800_CS-2025-5853C34","doi-asserted-by":"crossref","first-page":"F991","DOI":"10.1152\/ajprenal.00103.2016","article-title":"Loss of endothelin B receptor function impairs sodium excretion in a time- and sex-dependent manner","volume":"311","author":"Johnston","year":"2016","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2025071008014924800_CS-2025-5853C35","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","article-title":"The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators","volume":"338","author":"Krum","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"2025071008014924800_CS-2025-5853C36","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(09)61500-2","article-title":"A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Weber","year":"2009","journal-title":"Lancet"},{"key":"2025071008014924800_CS-2025-5853C37","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/HYPERTENSIONAHA.110.156976","article-title":"Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial","volume":"56","author":"Bakris","year":"2010","journal-title":"Hypertension"},{"key":"2025071008014924800_CS-2025-5853C38","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/jch.14517","article-title":"Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan","volume":"24","author":"Danaietash","year":"2022","journal-title":"J. of Clinical Hypertension"},{"key":"2025071008014924800_CS-2025-5853C39","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1161\/01.HYP.33.5.1169","article-title":"The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people","volume":"33","author":"Tiret","year":"1999","journal-title":"Hypertension"},{"key":"2025071008014924800_CS-2025-5853C40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/hmg\/ddg040","article-title":"Differential binding of transcription factor E2F-2 to the endothelin-converting enzyme-1b promoter affects blood pressure regulation","volume":"12","author":"Funke-Kaiser","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"2025071008014924800_CS-2025-5853C41","first-page":"739","article-title":"Genes encoding endothelin-converting enzyme-1 and endothelin-1 interact to influence blood pressure in women: the EVA study","volume":"22","author":"Funalot","year":"2004","journal-title":"J Hypertens (Los Angel)"},{"key":"2025071008014924800_CS-2025-5853C42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.cell.2017.06.049","article-title":"A genetic variant associated with five vascular diseases is a distal regulator of endothelin-1 gene expression","volume":"170","author":"Gupta","year":"2017","journal-title":"Cell"}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/139\/13\/769\/975385\/cs-2025-5853.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/139\/13\/769\/975385\/cs-2025-5853.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T12:01:56Z","timestamp":1752148916000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/139\/13\/769\/236293\/Endothelin-antagonists-for-hypertension-has-their"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,7,9]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20255853","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7]]}}}